应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
03347 泰格医药
未开盘 12-23 16:08:41
32.200
-0.050
-0.16%
最高
32.750
最低
31.550
成交量
65.06万
今开
32.750
昨收
32.250
日振幅
3.72%
总市值
278.51亿
流通市值
39.61亿
总股本
8.65亿
成交额
2,086万
换手率
0.53%
流通股本
1.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
泰格医药大跌2.84%！兴证全球基金旗下1只基金持有
金融界 · 12-23 20:47
泰格医药大跌2.84%！兴证全球基金旗下1只基金持有
泰格医药大跌2.84%！华泰柏瑞基金旗下1只基金持有
金融界 · 12-23 20:46
泰格医药大跌2.84%！华泰柏瑞基金旗下1只基金持有
泰格医药大跌2.84%！易方达基金旗下1只基金持有
金融界 · 12-23 20:46
泰格医药大跌2.84%！易方达基金旗下1只基金持有
泰格医药大跌2.84%！华宝基金旗下1只基金持有
金融界 · 12-23 20:46
泰格医药大跌2.84%！华宝基金旗下1只基金持有
海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性
时代周报-时代在线 · 12-23 19:30
海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性
长春高新(000661.SZ)子公司GS1-144获FDA新药临床试验申请默示许可
智通财经 · 12-23 18:53
长春高新(000661.SZ)子公司GS1-144获FDA新药临床试验申请默示许可
长春高新最新公告：子公司GS1-144获得美国FDA新药临床试验申请默示许可
证券之星 · 12-23 18:49
长春高新最新公告：子公司GS1-144获得美国FDA新药临床试验申请默示许可
百利天恒(688506.SH)自主研发创新生物药四特异性抗体GNC-038药物临床试验获批准
智通财经 · 12-23 18:06
百利天恒(688506.SH)自主研发创新生物药四特异性抗体GNC-038药物临床试验获批准
【百利天恒：GNC-038 四特异性抗体注射液项目治疗系统性红斑狼疮、类风湿关节炎获临床试验批准】金融界12月23日消息，百利天恒近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，其自主研发的创新生物药GNC-038的药物临床试验获得批准。GNC-038是一种靶向CD3、4-1BB、PD-L1和CD19的创新重组人源化四特异性抗体，是全球首个进入临床开发的四特异性治疗性抗体。除新获批的2个适应症外，目前已开展了1个Ia/Ib期和4个Ib/II期临床研究，适应症为急性淋巴细胞白血病和非霍奇金淋巴瘤等血液系统肿瘤。但药品在获得批准通知书后，尚需开展临床试验并经批准方可生产上市，具有不确定性。
金融界 · 12-23 17:56
【百利天恒：GNC-038 四特异性抗体注射液项目治疗系统性红斑狼疮、类风湿关节炎获临床试验批准】金融界12月23日消息，百利天恒近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，其自主研发的创新生物药GNC-038的药物临床试验获得批准。GNC-038是一种靶向CD3、4-1BB、PD-L1和CD19的创新重组人源化四特异性抗体，是全球首个进入临床开发的四特异性治疗性抗体。除新获批的2个适应症外，目前已开展了1个Ia/Ib期和4个Ib/II期临床研究，适应症为急性淋巴细胞白血病和非霍奇金淋巴瘤等血液系统肿瘤。但药品在获得批准通知书后，尚需开展临床试验并经批准方可生产上市，具有不确定性。
南新制药最新公告：帕拉米韦吸入溶液Ⅲ期临床试验方案通过审批
证券之星 · 12-23 17:41
南新制药最新公告：帕拉米韦吸入溶液Ⅲ期临床试验方案通过审批
【南新制药：帕拉米韦吸入溶液Ⅲ期临床试验方案获批】南新制药公告，公司自主研发的帕拉米韦吸入溶液Ⅲ期临床试验方案通过了牵头医院中国人民解放军总医院医学伦理委员会的审批，并获得《中国人民解放军总医院医学伦理委员会-药物临床试验伦理意见函》，在药物临床试验登记与信息公示平台完成公示。帕拉米韦吸入溶液是国家2.2类改良型新药，对临床流感防治具有重要意义。Ⅱ期临床试验结果表明，帕拉米韦吸入溶液在有效性方面能够有效缩短流感病毒转阴时间和症状持续时间，在安全性方面未发生严重程度为3级及以上的不良事件。公司将严格按照药物监管部门要求，推进Ⅲ期临床试验工作。
金融界 · 12-23 17:36
【南新制药：帕拉米韦吸入溶液Ⅲ期临床试验方案获批】南新制药公告，公司自主研发的帕拉米韦吸入溶液Ⅲ期临床试验方案通过了牵头医院中国人民解放军总医院医学伦理委员会的审批，并获得《中国人民解放军总医院医学伦理委员会-药物临床试验伦理意见函》，在药物临床试验登记与信息公示平台完成公示。帕拉米韦吸入溶液是国家2.2类改良型新药，对临床流感防治具有重要意义。Ⅱ期临床试验结果表明，帕拉米韦吸入溶液在有效性方面能够有效缩短流感病毒转阴时间和症状持续时间，在安全性方面未发生严重程度为3级及以上的不良事件。公司将严格按照药物监管部门要求，推进Ⅲ期临床试验工作。
石药(01093.HK)SYH2062注射液临床试验获批
阿斯达克财经 · 12-23 17:32
石药(01093.HK)SYH2062注射液临床试验获批
石药集团(01093)：SYH2062注射液获临床试验批准
智通财经 · 12-23 17:29
石药集团(01093)：SYH2062注射液获临床试验批准
一品红：子公司创新药APH01727片获得美国FDA临床试验批准
中国财富通 · 12-23 17:11
一品红：子公司创新药APH01727片获得美国FDA临床试验批准
莎普爱思最新公告：立他司特滴眼液获得临床试验批准通知书
证券之星 · 12-23 16:41
莎普爱思最新公告：立他司特滴眼液获得临床试验批准通知书
莎普爱思(603168.SH)：立他司特滴眼液获得临床试验批准通知书
智通财经 · 12-23 15:35
莎普爱思(603168.SH)：立他司特滴眼液获得临床试验批准通知书
港股异动 | 基石药业-B(02616)涨超3% 重磅产品CS2009已在澳大利亚递交临床试验申请
智通财经 · 12-23 14:31
港股异动 | 基石药业-B(02616)涨超3% 重磅产品CS2009已在澳大利亚递交临床试验申请
一品红(300723.SZ)：APH01727片获美国FDA临床试验批准
智通财经 · 12-23 11:46
一品红(300723.SZ)：APH01727片获美国FDA临床试验批准
南向资金12月20日净买入泰格医药10.67万股 连续3日增持
市场透视 · 12-23 09:30
南向资金12月20日净买入泰格医药10.67万股 连续3日增持
金十数据整理：每日港股市场要闻速递（12月23日 周一）
美港电讯 · 12-23 09:14
金十数据整理：每日港股市场要闻速递（12月23日 周一）
加载更多
公司概况
公司名称：
泰格医药
所属市场：
SEHK
上市日期：
--
主营业务：
杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":32.2,"timestamp":1734941321011,"preClose":32.25,"halted":0,"volume":650600,"delay":0,"floatShares":123000000,"shares":864948570,"eps":2.4891436,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.05,"latestTime":"12-23 16:08:41","open":32.75,"high":32.75,"low":31.55,"amount":20857342,"amplitude":0.037209,"askPrice":32.2,"askSize":600,"bidPrice":32.15,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.1782709792927681,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"listingDate":1596729600000,"adjPreClose":32.25,"dividendRate":0.018757,"openAndCloseTimeList":[[1734917400000,1734926400000],[1734930000000,1734940800000]],"volumeRatio":0.925981538942179,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":59.17,"timestamp":1734937437000,"preClose":60.9,"halted":0,"volume":9018448,"delay":0,"premium":"-48.82"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2493754779","title":"泰格医药大跌2.84%！兴证全球基金旗下1只基金持有","url":"https://stock-news.laohu8.com/highlight/detail?id=2493754779","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493754779?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:47","pubTimestamp":1734958022,"startTime":"0","endTime":"0","summary":"12月23日，泰格医药股票收盘大跌2.84%，天眼查资料显示，杭州泰格医药科技股份有限公司成立于2004年，位于杭州市，是一家以从事研究和试验发展为主的企业。数据显示，兴证全球基金旗下兴全商业模式优选混合进入泰格医药前十大股东，且为今年三季度新进。资料显示，兴证全球基金管理有限公司成立于2003年9月，董事长为杨华辉，总经理为庄园芳。目前，兴证全球基金共有2名股东，兴业证券股份有限公司持股51%、全球人寿保险国际公司持股49%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/23204746718156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","LU1146622755.USD","03347","BK1583","BK0077","300347","BK1576","LU1820825898.SGD","BK0028","BK0216","BK0174"],"gpt_icon":0},{"id":"2493754726","title":"泰格医药大跌2.84%！华泰柏瑞基金旗下1只基金持有","url":"https://stock-news.laohu8.com/highlight/detail?id=2493754726","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493754726?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:46","pubTimestamp":1734958019,"startTime":"0","endTime":"0","summary":"数据显示，华泰柏瑞基金旗下华泰柏瑞沪深300ETF进入泰格医药前十大股东，且为今年三季度新进。2018年3月至2018年10月任华泰柏瑞泰利灵活配置混合型证券投资基金的基金经理。2018年4月起任华泰柏瑞MSCI中国A股国际通交易型开放式指数证券投资基金的基金经理。目前，华泰柏瑞基金共有3名股东，PINEBRIDGE INVESTMENT LLC持股49%、华泰证券股份有限公司持股49%、苏州新区高新技术产业股份有限公司持股2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/23204646718157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0174","BK0216","BK1141","LU1146622755.USD","BK0028","BK1576","300347","BK1583","LU1820825898.SGD","BK0077","03347"],"gpt_icon":0},{"id":"2493754713","title":"泰格医药大跌2.84%！易方达基金旗下1只基金持有","url":"https://stock-news.laohu8.com/highlight/detail?id=2493754713","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493754713?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:46","pubTimestamp":1734958017,"startTime":"0","endTime":"0","summary":"12月23日，泰格医药股票收盘大跌2.84%，天眼查资料显示，杭州泰格医药科技股份有限公司成立于2004年，位于杭州市，是一家以从事研究和试验发展为主的企业。数据显示，易方达基金旗下易方达创业板ETF为泰格医药前十大股东，今年三季度增持。现任易方达基金管理有限公司基金经理。曾任招商银行资产托管部基金会计,易方达基金管理有限公司核算部基金核算专员、指数与量化投资部运作支持专员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/23204646718158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","LU1820825898.SGD","BK1141","BK0174","BK0216","03347","LU1146622755.USD","BK1576","BK0077","BK1583","300347"],"gpt_icon":0},{"id":"2493547927","title":"泰格医药大跌2.84%！华宝基金旗下1只基金持有","url":"https://stock-news.laohu8.com/highlight/detail?id=2493547927","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493547927?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:46","pubTimestamp":1734958015,"startTime":"0","endTime":"0","summary":"12月23日，泰格医药股票收盘大跌2.84%，天眼查资料显示，杭州泰格医药科技股份有限公司成立于2004年，位于杭州市，是一家以从事研究和试验发展为主的企业。数据显示，华宝基金旗下华宝中证医疗ETF为泰格医药前十大股东，今年三季度增持。2023年4月起任华宝中证沪港深新消费指数型证券投资基金基金经理。2023年12月起任华宝标普中国A股红利机会交易型开放式指数证券投资基金基金经理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/23204646718159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","LU1820825898.SGD","BK1141","BK0174","BK0216","03347","LU1146622755.USD","BK1576","BK0077","BK1583","300347"],"gpt_icon":0},{"id":"2493755367","title":"海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=2493755367","media":"时代周报-时代在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493755367?lang=zh_cn&edition=full","pubTime":"2024-12-23 19:30","pubTimestamp":1734953400,"startTime":"0","endTime":"0","summary":"2024年年中，海金格的IPO申报获北交所受理；12月12日，海金格回复了北交所的第二轮问询函。2024年上半年，三家同行可比公司扣非归母净利润均出现下滑，海金格却逆势高速增长，北交所连续两轮问询其业绩增长的真实合理性。海金格拟新增网点与部分分公司存在重合，但各地分公司现有人员数量较少，北交所询问新增网点是否存在闲置风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-23/doc-ineancvn9227140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","LU1820825898.SGD","BK1576","BK1583","LU1146622755.USD","BK1141","BK0028","BK0174","301333","BK0276","300347","301257","BK0216","688710","601066","BK0077"],"gpt_icon":0},{"id":"2493471730","title":"长春高新(000661.SZ)子公司GS1-144获FDA新药临床试验申请默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2493471730","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493471730?lang=zh_cn&edition=full","pubTime":"2024-12-23 18:53","pubTimestamp":1734951187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，根据美国食品药品监督管理局(简称“FDA”)相关规则，公司子公司长春金赛药业有限责任公司(简称“金赛药业”)GS1-144已在FDA获得新药临床试验申请默示许可。该药品适应症：绝经期血管舒缩症。日前，金赛药业GS1-144新药II期临床试验申请已达到FDA规定的默示许可期，该项目即可在美国开始进行临床试验。金赛药业将按照FDA相关要求，有序开展相关后续工作。如子公司临床试验进展顺利，将有利于公司拓宽业务结构、优化产品结构，并丰富完善战略领域产品线布局、提升公司核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK1141","03347","BK0075","BK1576","BK0046","000661","BK0239","BK1583","BK0057"],"gpt_icon":0},{"id":"2493730411","title":"长春高新最新公告：子公司GS1-144获得美国FDA新药临床试验申请默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2493730411","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493730411?lang=zh_cn&edition=full","pubTime":"2024-12-23 18:49","pubTimestamp":1734950966,"startTime":"0","endTime":"0","summary":"长春高新公告，子公司金赛药业的GS1-144已在美国FDA获得新药临床试验申请默示许可，用于在美国境内开展药品II期临床试验。GS1-144适应症为绝经期血管舒缩症，该病影响多达80%的绝经期女性。GS1-144是金赛药业自主研发的NK3R小分子拮抗剂，在中国为化药1类新药，美国为505b1类新药。2023年11月，该药品在同一适应症的临床试验申请已获得中国国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300028106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","BK1583","BK0188","BK1141","BK0028","000661","BK0046","BK0057","BK0239","BK0075"],"gpt_icon":0},{"id":"2493273280","title":"百利天恒(688506.SH)自主研发创新生物药四特异性抗体GNC-038药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2493273280","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493273280?lang=zh_cn&edition=full","pubTime":"2024-12-23 18:06","pubTimestamp":1734948410,"startTime":"0","endTime":"0","summary":"通财经APP讯，百利天恒(688506.SH)公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药四特异性抗体GNC-038的药物临床试验获得批准。据悉，GNC-038是公司依靠全球领先的创新多特异性抗体药物研发平台(GNC平台)自主研发的一种靶向CD3、4-1BB、PD-L1和CD19的创新重组人源化四特异性抗体，是全球首个进入临床开发的四特异性治疗性抗体。除本次新获批的2个适应症外，目前，GNC-038已开展了1个Ia/Ib期和4个Ib/II期临床研究，适应症为急性淋巴细胞白血病和非霍奇金淋巴瘤等血液系统肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","159839","BK1576","BK1583","BK1141","BK0239","688506"],"gpt_icon":0},{"id":"2493734438","title":"【百利天恒：GNC-038 四特异性抗体注射液项目治疗系统性红斑狼疮、类风湿关节炎获临床试验批准】金融界12月23日消息，百利天恒近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，其自主研发的创新生物药GNC-038的药物临床试验获得批准。GNC-038是一种靶向CD3、4-1BB、PD-L1和CD19的创新重组人源化四特异性抗体，是全球首个进入临床开发的四特异性治疗性抗体。除新获批的2个适应症外，目前已开展了1个Ia/Ib期和4个Ib/II期临床研究，适应症为急性淋巴细胞白血病和非霍奇金淋巴瘤等血液系统肿瘤。但药品在获得批准通知书后，尚需开展临床试验并经批准方可生产上市，具有不确定性。","url":"https://stock-news.laohu8.com/highlight/detail?id=2493734438","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493734438?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:56","pubTimestamp":1734947804,"startTime":"0","endTime":"0","summary":"金融界12月23日消息，百利天恒近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，其自主研发的创新生物药GNC-038的药物临床试验获得批准。GNC-038是一种靶向CD3、4-1BB、PD-L1和CD19的创新重组人源化四特异性抗体，是全球首个进入临床开发的四特异性治疗性抗体。除新获批的2个适应症外，目前已开展了1个Ia/Ib期和4个Ib/II期临床研究，适应症为急性淋巴细胞白血病和非霍奇金淋巴瘤等血液系统肿瘤。但药品在获得批准通知书后，尚需开展临床试验并经批准方可生产上市，具有不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/23175646706774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","159839","BK1576","BK1583","BK4023","BK1141","PD","LU1169589451.USD","LU1169590202.USD","BK0239","688506"],"gpt_icon":0},{"id":"2493973147","title":"南新制药最新公告：帕拉米韦吸入溶液Ⅲ期临床试验方案通过审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2493973147","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493973147?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:41","pubTimestamp":1734946872,"startTime":"0","endTime":"0","summary":"南新制药公告，公司在研项目帕拉米韦吸入溶液Ⅲ期临床试验方案通过牵头医院中国人民解放军总医院医学伦理委员会的审批，获得开展该产品Ⅲ期临床试验许可。帕拉米韦吸入溶液是公司自主研发的国家2.2类改良型新药，已完成Ⅱ期临床试验，结果显示能够有效缩短流感病毒转阴时间和症状持续时间，安全性良好。公司将严格按照药物监管部门要求，遵循药物临床试验质量管理规范，快速推进Ⅲ期临床试验工作。但药品最终疗效需经国家药品监督管理局批准后方可上市，存在无法获批上市销售的风险。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300024804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","03347","688189","BK1576","BK0239","BK1583"],"gpt_icon":0},{"id":"2493731849","title":"【南新制药：帕拉米韦吸入溶液Ⅲ期临床试验方案获批】南新制药公告，公司自主研发的帕拉米韦吸入溶液Ⅲ期临床试验方案通过了牵头医院中国人民解放军总医院医学伦理委员会的审批，并获得《中国人民解放军总医院医学伦理委员会-药物临床试验伦理意见函》，在药物临床试验登记与信息公示平台完成公示。帕拉米韦吸入溶液是国家2.2类改良型新药，对临床流感防治具有重要意义。Ⅱ期临床试验结果表明，帕拉米韦吸入溶液在有效性方面能够有效缩短流感病毒转阴时间和症状持续时间，在安全性方面未发生严重程度为3级及以上的不良事件。公司将严格按照药物监管部门要求，推进Ⅲ期临床试验工作。","url":"https://stock-news.laohu8.com/highlight/detail?id=2493731849","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493731849?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:36","pubTimestamp":1734946593,"startTime":"0","endTime":"0","summary":"南新制药公告，公司自主研发的帕拉米韦吸入溶液Ⅲ期临床试验方案通过了牵头医院中国人民解放军总医院医学伦理委员会的审批，并获得《中国人民解放军总医院医学伦理委员会-药物临床试验伦理意见函》，在药物临床试验登记与信息公示平台完成公示。帕拉米韦吸入溶液是国家2.2类改良型新药，对临床流感防治具有重要意义。Ⅱ期临床试验结果表明，帕拉米韦吸入溶液在有效性方面能够有效缩短流感病毒转阴时间和症状持续时间，在安全性方面未发生严重程度为3级及以上的不良事件。公司将严格按照药物监管部门要求，推进Ⅲ期临床试验工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/23173646705725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK0239","BK1576","BK1583","688189","03347"],"gpt_icon":0},{"id":"2493731997","title":"石药(01093.HK)SYH2062注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2493731997","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493731997?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:32","pubTimestamp":1734946320,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，旗下自主研发的化学1类新药SYH2062注射液(双链小干扰RNA(siRNA)药物)，已获国家药监局批准，可以在中国开展临床试验。该产品是一款通过偶联乙酰半乳糖胺(GalNAc)递送的siRNA药物，可以靶向抑制血管紧张素原(AGT)，适用于治疗高血压。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405993/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1960683339.HKD","IE00B031HY20.USD","01093","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU1807302812.USD","LU1226288170.HKD","IE00B543WZ88.USD","LU0880133367.SGD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0501845795.SGD","BK1521","BK1576","LU1008478684.HKD","LU0326950275.SGD","03347","LU1152091168.USD","BK1515","LU1226287529.USD","BK1191","LU1993786604.SGD","LU0072913022.USD","SG9999004220.SGD","BK1583","LU1226288253.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287875.USD","BK1141","LU0140636845.USD","IE0008368742.USD","IE0008369823.USD"],"gpt_icon":0},{"id":"2493739233","title":"石药集团(01093)：SYH2062注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2493739233","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493739233?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:29","pubTimestamp":1734946153,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的化学1类新药SYH2062注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。该产品是一款通过偶联乙酰半乳糖胺递送的si RNA药物，可以靶向抑制血管紧张素原，适用于治疗高血压。临床前研究显示，该产品的药物活性作用时间明显长于同类型si RNA产品，预期具有药物作用效果持久、安全性良好及患者依从性高等差异化优势，有较大临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","LU0501845795.SGD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","BK1576","IE00B031HY20.USD","LU0072913022.USD","BK1191","LU1152091168.USD","IE0008369823.USD","BK1583","01093","LU1951186391.HKD","LU0140636845.USD","LU0326950275.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1226288170.HKD","LU1993786604.SGD","IE0008368742.USD","BK1515","BK1141","LU1226287875.USD","LU1226287529.USD","LU1152091754.HKD","03347","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1807302812.USD","BK1521","LU0067412154.USD","LU1226288253.USD","LU1960683339.HKD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2493279736","title":"一品红：子公司创新药APH01727片获得美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2493279736","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493279736?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:11","pubTimestamp":1734945066,"startTime":"0","endTime":"0","summary":"中国财富通12月23日 - 一品红（300723）公告称，近日，公司全资子公司广州一品红制药有限公司收到美国食品药品监督管理局（FDA）下发的关于同意公司子公司自主研发的创新药物APH01727片临床试验的函。APH01727片是公司自主研发的一种高活性高选择性的胰高血糖素样肽-1受体激动剂（GLP⁃1RA），目标成为每天给药一次的口服小分子GLP-1R激动剂，拟用于2型糖尿病的治疗。目前，尚未在国内、外批准上市。APH01727片获得临床试验批准对公司短期的财务状况、经营业绩不构成重大影响。该产品需要按药品注册相关规定要求开展临床试验，待临床试验成功后按法定程序申报生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=a9f5dllL0xk%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","03347","BK1576","BK1583","BK0239","BK1161","BK1141","300723","06978","BK1574"],"gpt_icon":0},{"id":"2493735856","title":"莎普爱思最新公告：立他司特滴眼液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2493735856","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493735856?lang=zh_cn&edition=full","pubTime":"2024-12-23 16:41","pubTimestamp":1734943271,"startTime":"0","endTime":"0","summary":"莎普爱思公告，公司近日收到国家药监局核准签发的立他司特滴眼液《药物临床试验批准通知书》，公司拟于条件具备后开展临床试验。该药品适用于治疗干眼症（DED）的症状和体征。截至公告披露日，立他司特滴眼液项目累计研发投入约1463.40万元人民币。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300022079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239","BK1141","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2493478479","title":"莎普爱思(603168.SH)：立他司特滴眼液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2493478479","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493478479?lang=zh_cn&edition=full","pubTime":"2024-12-23 15:35","pubTimestamp":1734939320,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)发布公告，近日，公司的立他司特滴眼液获得国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号：2024LP02979)，公司拟于条件具备后开展临床试验。该药品适用于治疗干眼症(DED)的症状和体征。根据我国药品注册相关法律法规要求，公司在取得药物临床批准后，须按照审批内容进行临床研究并经国家药监局审批通过后方可上市。截至公告披露日，立他司特滴眼液项目累计研发投入约1,463.40万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603168","BK0239","BK1141","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2493078659","title":"港股异动 | 基石药业-B(02616)涨超3% 重磅产品CS2009已在澳大利亚递交临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2493078659","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493078659?lang=zh_cn&edition=full","pubTime":"2024-12-23 14:31","pubTimestamp":1734935467,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超3%，截至发稿，涨3.04%，报2.37港元，成交额400.09万港元。消息面上，基石药业今日宣布，公司用于治疗多种实体瘤的管线2.0重磅产品CS2009已在澳大利亚递交临床试验申请。基石药业计划于2025年初首先在澳洲启动CS2009的全球多中心、首次人体研究，未来将陆续扩展至中国及美国。基石药业已在第39届癌症免疫治疗学会年会上公布了CS2009的临床前数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","02616","BK1583","BK1574","BK1576","BK1161"],"gpt_icon":0},{"id":"2493830201","title":"一品红(300723.SZ)：APH01727片获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2493830201","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493830201?lang=zh_cn&edition=full","pubTime":"2024-12-23 11:46","pubTimestamp":1734925593,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司(简称“一品红制药”)收到美国食品药品监督管理局(FDA)下发的关于同意公司子公司自主研发的创新药物APH01727片临床试验的函。APH01727片是公司自主研发的一种高活性高选择性的胰高血糖素样肽-1受体激动剂，目标成为每天给药一次的口服小分子GLP-1R激动剂，拟用于2型糖尿病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","BK1576","BK0239","300723","BK1583"],"gpt_icon":0},{"id":"2493272702","title":"南向资金12月20日净买入泰格医药10.67万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2493272702","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493272702?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:30","pubTimestamp":1734917422,"startTime":"0","endTime":"0","summary":"12月20日, 南向资金增持泰格医药10.67万股，连续3日增持。截止当日收盘，港股通共持有泰格医药5735.33万股，占流通股46.57%。泰格医药近5个交易日下跌4.59%，港股通累计减持4.43万股；近20个交易日下跌0.31%，港股通累计增持132.58万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093304ab8c8b37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093304ab8c8b37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1583","BK1141","BK1576"],"gpt_icon":0},{"id":"2493274515","title":"金十数据整理：每日港股市场要闻速递（12月23日 周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2493274515","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493274515?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:14","pubTimestamp":1734916448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1150","BK1583","BK1148","BK1191","BK0012","BK0276","02276","08031","BK1165","HSCEI","BK0183","02611","06837","600837","BK0070","BK1576","HSTECH","BK1123","BK1141","BK0188","YANG","159646","BK1147","00293","06185","BK0201","BK1564","BK1201","01373","BK1561","BK1515","03347","601211","BK0184","07226","BK1161","BK0028","BK1222","BK1574","00711"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.1625},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0719}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.1663}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.100468},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009723},{"month":3,"riseRate":0.75,"avgChangeRate":0.001875},{"month":4,"riseRate":0.25,"avgChangeRate":-0.034639},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.041866}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}